

**REMARKS**

Claims 1 and 3-14 were pending in the present application and were rejected. Claims 1, 3-5, 7, 11, 13 and 14 are herein amended. Claims 6, 8-10 and 12 are herein cancelled without prejudice.

**Applicants' Response to Claim Rejections under 35 U.S.C. §112**

**Claims 7-9 were rejected under 35 U.S.C. §112, second paragraph, as being indefinite for failing to particularly point out the and distinctly claim the subject matter which applicant regards as the invention.**

The Office Action states that the phrase "for a long term" is a relative term, and the metes and bounds of what is intended cannot be determined. In response, Applicants herein amend claim 7 to delete this language, and to recite preserving the nucleic acids for at least 120 hours. Please see amended claim 7. Accordingly, Applicants herein cancel claims 8 and 9. Favorable reconsideration is respectfully requested.

**Applicants' Response to Claim Rejections under 35 U.S.C. §102**

**Claims 1, 3-6 and 10-14 were rejected under 35 U.S.C. §102(b) as being anticipated by Ohno et al. (J. of the Electrochemical Society 148(4): E168-E170 (2001)).**

It is the position of the Office Action that Ohno discloses the invention as claimed. Applicants first discuss claim 1. Ohno discloses the mixing of ethylimidazolium tetrafluoroborate (EtImBF<sub>4</sub>) with DNA to obtain a flexible film. As illustrated at the top of the

first column on page E169, EtIMBF<sub>4</sub> contains an imidazolium cation and a BF<sub>4</sub><sup>-</sup> anion. Applicants herein amend claim 1 to remove BF<sub>4</sub><sup>-</sup> from the Markush group of anions. As such, Applicants respectfully submit that Ohno does not disclose the embodiments as claimed. Claim 10 is herein cancelled, since its subject matter has been incorporated into claim 1.

Next, Applicants discuss the claim term “halide ion.” It is the position of the Office Action that that BF<sub>4</sub><sup>-</sup> is “a halide ion,” even though this interpretation contradicts the citation provided, which states that “The halide anions are fluoride (F<sup>-</sup>), chloride (Cl<sup>-</sup>), bromide (Br<sup>-</sup>), iodide (I<sup>-</sup>) and astatide (At<sup>-</sup>).” In other words, there are only five possible halide anions, and BF<sub>4</sub><sup>-</sup> is not one of them. Although BF<sub>4</sub><sup>-</sup> has a negative charge and includes a halogen, it is not is a “halide ion.”

However, in order to expedite examination, Applicants herein amend the claims to remove the recitation of “a halide ion” and add the recitation of “Cl<sup>-</sup>, Br<sup>-</sup> and I<sup>-</sup>.” Applicants do not recite fluoride (F<sup>-</sup>) and astatide (At<sup>-</sup>) at this time. Please see the amended claims. Ohno does not disclose or suggest one of the recited anions, it cannot anticipate the claimed embodiments.

With respect to claim 4, the Office Action cites page E168, second paragraph to show that EtIMBF<sub>4</sub> is a neutralized ionic liquid. With respect to claim 5, it appears that the Office Action regards this claim as reciting an intended use, which does not carry patentable weight. Applicant respectfully submits that claims 4 and 5 are patentable at least due to their dependency on claim 1.

With respect to claim 6, Applicants herein cancel this claim. Thus, the rejection of claim 6 is moot.

With respect to claims 11-14, the Office Action alleges that these claims are rejected for the same reasons as discussed with respect to claims 1, 3-6 and 10. In response, Applicants respectfully submit that claims 11, 13 and 14 are patentable for similar reasons as claims 1 and 3, above. Similar to claim 10, claim 12 is herein cancelled, since its subject matter has been incorporated into claim 11. Favorable reconsideration is respectfully requested.

**Claim Rejections – 35 U.S.C. §§102/103**

**Claims 7 and 8 are rejected under 35 U.S.C. §102(b) as anticipated by or, in the alternative, under 35 U.S.C. §103(a) as obvious over Ohno.**

It is the position of the Office Action that Ohno discloses the method as claimed, with the exception of explicitly teaching that “the nucleic acid dissolved in their ionic liquid is preserved.” The Office Action argues that this is inherent to the ionic liquids of Ohno.

In response, Applicants herein incorporate the allowable subject matter of claim 9 into claim 7. Applicants herein cancels claim 8. Thus, this rejection is moot.

**Allowable Subject Matter**

The Office Action indicates that claim 9 would appear to be allowable if rewritten to overcome the rejections under 35 U.S.C. §112. Applicants herein re-write claim 9 to be in independent form.

Application No.: 10/593,898  
Art Unit: 1634


Amendment  
Attorney Docket No.: 063057

For at least the foregoing reasons, the claimed invention distinguishes over the cited art and defines patentable subject matter. Favorable reconsideration is earnestly solicited.

Should the Examiner deem that any further action by applicants would be desirable to place the application in condition for allowance, the Examiner is encouraged to telephone applicants' undersigned attorney.

If this paper is not timely filed, Applicants respectfully petition for an appropriate extension of time. The fees for such an extension or any other fees that may be due with respect to this paper may be charged to Deposit Account No. 50-2866.

Respectfully submitted,  
**WESTERMAN, HATTORI, DANIELS & ADRIAN, LLP**



Ryan B. Chirnomas  
Attorney for Applicants  
Registration No. 56,527  
Telephone: (202) 822-1100  
Facsimile: (202) 822-1111

RBC/nrp